NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Not that important.
Primary GBM's are almost always IDH wildtype. Likely 90-95% of the trial.
IDH mutations are hallmark of secondary GBM.
Only a few percent.
As Senti says, they just need to show that they didn't artificially stack the trial full of secondary GBM's. Which I'm sure they didn't.

My guess is that a regulator asked for this late in the day, so NWBO have to oblige.